Biogen’s targeted ALS treatment is reversing decline in some patients. Can more be helped?

Summary

Biogen's Qalsody, the first FDA-approved drug targeting a genetic cause of ALS, is demonstrating symptom improvement and disease stabilization in some patients three years post-approval, raising questions about expanding treatment to additional patient populations.